Cargando…
Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates
The enhanced transmissibility and immune evasion associated with emerging SARS-CoV-2 variants demands the development of next-generation vaccines capable of inducing superior protection amid a shifting pandemic landscape. Since a portion of the global population harbors some level of immunity from v...
Autores principales: | Walters, Jewell N., Schouest, Blake, Patel, Ami, Reuschel, Emma L., Schultheis, Katherine, Parzych, Elizabeth, Maricic, Igor, Gary, Ebony N., Purwar, Mansi, Andrade, Viviane M., Doan, Arthur, Elwood, Dustin, Eblimit, Zeena, Nguyen, Brian, Frase, Drew, Zaidi, Faraz I., Kulkarni, Abhijeet, Generotti, Alison, Joseph Kim, J, Humeau, Laurent M., Ramos, Stephanie J., Smith, Trevor R.F., Weiner, David B., Broderick, Kate E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977452/ https://www.ncbi.nlm.nih.gov/pubmed/35428500 http://dx.doi.org/10.1016/j.vaccine.2022.03.060 |
Ejemplares similares
-
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
por: Tebas, Pablo, et al.
Publicado: (2021) -
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
por: Andrade, Viviane M., et al.
Publicado: (2021) -
578. INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants
por: Andrade, Viviane M, et al.
Publicado: (2021) -
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
por: Tebas, Pablo, et al.
Publicado: (2020) -
One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model
por: Gooch, Karen E., et al.
Publicado: (2021)